the doctor should know about MEGAMIN and TMAZ !
Prof. Kresimir Pavelic MD. Ph.D.
Head of Department of molecular medicine, Ruder Boskovic Institute
The active substance with its strong characteristic of the ion exchange is one of a kind of zeolits, which was micronised by a special patented procedure. The mentioned procedure increases the specific surface, the capacity of the absorption of liquids, it increases the electrostatic load of the damaged place on the surface of the active powder, it frees the crystalline water connections of the inside structures of the crystal and finally it enlarges the capacity of the ion exchange.
Published biological data onnon-active zeolits, show a protective effect of this mineral against the toxic bacterial effects or poisons and offers protection against osteoporosis. Activated zeolits have meanwhile considerable, expressive effect on the organism and on illnesses.
Recent work point out that oxidoreductives control free radical, numerous processes in the communication of the signals and the expression of the genes. Recently it was described that these processes could be involved in the development of some important diseases malignant, cardiovascular, diabetic, arthritic, neurodegenerative illnesses etc. Therefore, it is not surprising that some powerful pharmaceutical companies are trying to manufacture products, which can control the redox-proceedings in cell tissues. Worldwide there are two groups of these products highlighted: One is based on the manufacture of strong, liquid and the other bases on solid oxidant and antioxidant. In the development of the first group scientists of the USA and Japan stresses out, meanwhile the group of Zagreb is advanced in biomedical reserach on solid substances.
The basic substance of the solid oxidant and antioxidant is labeled with the code-letter TMAZ and is being investigated intensively in the Ruder Boskovic Institute and other institutes in Croatia. To the topic "The investigation of the toxicology ofTMAZ and the effect on various physiological systems of the organism" there was arranged a conference. The organizers of this conference was the institution "Ruder Boskovic", Department of Molecular Medicine and the Business-Innovations-Center of Croatia "BICRO". Following experts and scientists gave a talk about the results of the effrct of TMAZ on various organic systems and dermatological disesases cancer as well as diabetes: I. Hunjadi, J. Tocilj, J. Lipozencic, M. Jurin. A. Svarc, B. Radosevic-Stasic, M. Hadzija, Lj, Bedrica, S. Ivkovic, M. Kralj, V. Hegedusic, T. Marotti, J. Pavelic, M. Slijepcevic, V. Vucevac, M. Stiplosek.
At the second part of the symposium, temporary clinical experiences of the recently registered dietetic preparation MEGAMIN which contains 50 % active substance of TMAZ and some other components, like calcium, magnesium and iron, were presented.
Experiences on the application of this preparation on people with advance malignant tumors and systemic illnesses were presented. The temporary clinical results encourages using this preparation on seriously ill people, simultaneously it highlights how important it is to carry out "double-blinded" clinical trial as soon as possible. The conclusion of the symposium is to intensify and make faster the basic research and to start with controlled clinical study of people with advanced nesoplastic disense. The main problem, which could endanger the research and maybe even stop them, is still the unsolved financing of this project.
TMAZ reduces the growth ofhuman cancer cells in vitro. In addition it reduces the growth of some experimental tumors of mice and spontaneous tumours on dogs. Very good effects were observed on spontaneous tumors of dogs: lung cancer, prostate sklin cancer and lymphoma. Also recorded were improvements of hematological and biochemical parameters and the general condition of the animal.
Clinical experiences, basing on anegdotal cases of more than 200 patient, were exclusively made by observations of effects of MEGAMIN and this in a relatively short time. Temporary increase in body temperature observedin some cases. Some people withliver disease had short-term diarrhea. After 3 days all patient were in a good general condition. People, treated with chemotherapy, had no more fungus in their mouthand the side effectsof chemotherapy and radiotherapy were much lower.Some hematological and biochemical indicators normalized (SE, E, L, Tr, gGt, AST, ALT). EspeciallyLDH. The diffusion-capacity of the lungs and the contractions of the heart muscle increase. Strikingly the general condition of the ill people got better, they gain weight and in most cases their hunger feeling got stronger. The request for analgesic has been reduced or totally disappeared. In most cases depressions and sleeplessness disappeared; life will has been woken up.
The group of patients, which wereunder X-ray treatment, or who had chemotherapy behind them, had an essential better general condition, the pains were reduced and the recovery is becoming faster.
Recently theRuder Boskovic Institute and the Ministry of Science and Technology Republlic of Croatia have signed a contract about the scientific investigation of the preparation TMAZ, with the aim to prove the biomedical characteristics of this substance. In the meantime the dietetic preparation Megamin is available, which we will soon suggest for a clinical trial. To the question if a doctor should give the MEGAMIN to his patients, I can only agree, especially if patient suffers from advanced cancer. I personally think, that the better successes will be proved by taking in MEGAMIN in early stage of disease. Our preliminaray results show TMAZ can help, where the medicine has no suitable solutions; however, it is too early to talk about it.
This article was published in "Medical News", year 26., No 141, Nov. 1998
Clinical obseravations at the taking of dietetic preparation MEGAMIN
Jadranka Tocilj, MD Ph.D.
Clinical center, depart. for lung diseases, 21 000 Split
The dietetic preparation MEGAMIN , which contains as the basic substance TMAZ, was taken by several patients with various kinds of illnesses under medical supervision, with the aim to be able to judge about the effect of this preperation on clinical indicators, the general condition of the persons who fell ill, as well as the usefulness / adequacy on further clinical observations.
The first group are patients with breast cancer ( 18 ) as well as lung cancer and pleura cancer ( 6 ), prostate cancer ( 5 ), primary liver cancer ( 5 ), ovary cancer ( 3 ), malicious brain tumours of th degree II/III, gullet cancer ( 1 ), and other ( 17 ).
The equality of all patients is that they all have been treatedwith chemotherapy and ray treatment therapies or are still getting them, through which they achieved degraded haematologiacal results ( in most cases anaemia and a deficit of leucozyths and thrombozyths ), as well as increased enzymes gGT, LDH, alkaline phosphates. The general condition was bad, loss of strengh and pain.
The second group is patients with lsystem illnesses of the lupus ( 2 ), coagenosis ( 3 ), and lulng fibrosis ( 3 ).
The third group is various, beginning with people with diabetes, as well as various neurothies up to inglammations of the muscle system ( miocitis ), as well as hepatitis B and C ( 3 ).
The duration of taking and the dossage ( TMAZ ):
The first group has taken on average 15 capsules daily, while heavily falllen ill people took the capsules also at night.
If a person has been given chemotherapy he has taken up to 20 capsules.
The second group has taken 10 capsules daily.
The third group of the patients has taken 6 – 8 capsules daily.
The combination of powder and Megamin, that means 5 teaspoons powder and 10 capsules of Megamin have improved to the best combination for heavy illnesses.
At a small number of patients higher temperatureas and sweat separations were stated and patients who had liver cancer had diarroea, peace, good sleep, a stronger urinating or sweating and some had headaches.
The beginning of th effect of the taken preparation:
After three days the general condition has become better of all patients. At persons, who have been treated with chemotherapy, has been stated that funguses in the mouth area and in the gullet have disappered and they had a better compatibility of the chemotherapy.
At the first group of the patient's normal haematological biochemical indicators have been measured.
It has been stated that the sedimentation, the red and white blood corpuscles as well as the thrombozyths have become already 7 days aftera the beginning of the taking the capsules. After approximately 15 days the enuymes ( gGT, AST, ALT ) have mormalised, too, especially fast the LDH normalised, the alkaline phospates have dropped a little but have not normalised.
Intwo cases of liver cancer the reduction of free liquids in the stomach has been observed, the general condition became better.
The general condition of all patients has become importantly better; they gain weight and have needed to eat something.
At the second group of the patients beside the usual haematological biochemiocal indicators also the functional indicators of the lung the capacity of diffusion and the oxygen were stated at their resting condition. It has observed that the enzymes and the LDH have normalised, in addition the capacity of the contraction of the heart muscle, because this is a reason for the strengthening of the capacity of lung diffusion ( this assumption is still being worked out ).
At the third group the rose of sugar was stated while taking 6 capsules of TMAZ daily, the general condition of the patients became better.
The reduction of pain of the muscle system has been watched with measures of the milk acid.l
The homeostatic mechanism is being restored and the milk acid salary in the blood sinks.
Persons with hepatitis B and C had a fast normallisation of the enzymes.
Every 15 days the haematological biomechanical indicators were stated, and every patient has a detailed medical documentation, which in the equality has not been worked out on the regulation of the subject. The above mentioned observations have not been stated due to statistic work out and not due to the basis of a clinical examination.
shown is the basis for a clinical examination, which is valuable
to be continued in a defined program.
The application of TMAZ for the preparation of dietetic products
Prof.Vesna Hegedusi Ph.D., Prof. Vesna Stehlik-Tomas Ph.D., Milica Gacic MD
Diet-Biotechnological University, 10000 Zagreb, Pierottijeva 6
The preparation with the name TMAZ is an tribomechanically-activated zeolit (mineral), in which specific physical-chemical characteristics were found by earlier temporal examinations. The first examinations with the preparation, which were made in Croatia, began in spring of 1997 in the University of Diet-Biotechnology in Zagreb and were intend to go in several areas. First of all the chemical compositions and some physical characters were defined and after that the effect of TMAZ on microbiological activity.
The particle quantity, the dividing of the particle quantity, the arithmetical, middle diameter and the specific surface of the physical characteristic have been determined.
The following has been stated:
All particles have smaller diameter than 20 µm
98% of the particles have a smaller diameter than 4,3 µm
90% of the particles have a smaller diameter than 2,67 µm
72% of the particles have a smaller diameter than 1,95 µm
52% of the particles have a smaller diameter than 1,6 µm
The largest particle share (28,4%%) has a diameter between 0,5 and 1,32 µm
The arithmetic middle diameter is 2,68 µm
In proportion to the non-activated zeolit the average size of the particles of TMAZ is 8 times smaller, while the specific surface is 3 times bigger than before the activating, it is 1,3488 m2/g.
Further examination have been made to prove the possible influence of TMAZ on microbiological activity, especially on the activity of some kinds of bacteria, which are interesting for the diet industry, and baking yeast.
The results have shown that the effect of TMAZ on single kinds of bacteria are various, depending on the added quantity of TMAZ, the kind and the initial number of bacteria and the time and temperature of the incubation. Stated was the important hindering of growth of the bacteria Lactobacillus brevis, Escherichia coli and Salmonella enteritidis.
Because of the great importance of the yeast Saccharomyces cerevisiae for the diet industry, they wanted to whether the addition TMAZ has any effect on fermentation activity of this yeast on the suspension of flour. For this reason examinations were made on the following way:
with sterilized and non-sterilized TMAZ
with various quantities ofTMAZ, which moved between 0,5 to 20% on quantity of the flour (basically 0,25 to 10%)
the fermentation activity has been measured after 30, 60 and 90 minutes.
The results showed,that the addition of sterilized and non-sterilized TMAZ accelerate the fermentation activity of yeast, which has to be put down on the presence of microelements (Zinc, Chrome, Copper and Manganese) which are known that they accelerate the growth of yeast. In addition it has been stated that sterilized TMAZ has important greater effects than non-sterilized TMAZ, from which the conclusion can be drew that non-sterilized TMAZ has micro organisms, which have effects of inhibition on the activity of yeast. If the activity of yeast is compared with the various shares of TMAZ than it is obvious that it greatest effect was determined by the addition of 1% of TMAZ (on the quantity of flour). On the greater share of TMAZ the positive effect on the activity of yeast was smaller.
Further examinations were intended on the preparation of single diet products which have been enriched with TMAZ. They went into two directions:
1.Enrich available diet products with a special share of TMAZ, to improve the functional and physiological characteristics or the enlargement of their biological values (i.e. the raise of the stability of mushy fruit and vegetable juices, creamy desserts and similar). It has been proved that the addition up to 5% of TMAZ has favorable effect on the stated characters of mushy substances.
2.Prepare dietetic preparation, in which an important quantity of TMAZ is present (up to 50%). According to "The Service Instruction about the physical correctness of Addition" (NN 46/94) dietetic ingredients are ingredients of special compositions or processing processes, as well as ingredients enriched with vitamins and minerals and other biologic valuable substances. This dietetic preparation was prepared and named as MEGAMIN® with declaration: 1g contains 200mg of Calcium (25% RDA), 120mg of Magnesium (40% RDA), 9mg of Iron (75% RDA) and its energetic value is 0 kJ. Its chemical composition and micro-biological valuation has been made by an official analysis in an authorized laboratory.
Report about the experiences (results) of observation at the giving of TMAZ orally in the form of capsules .
Slavko Ivkovic MD.
The application of the dietetic preparation MEGAMIN at patients that suffer of malignant illnesses, anecdotal cases at patients with protracted virus hepatitis, decompensated liver cirrhoses as well as diabetes and other degenerative illnesses.
1. Patients with malignant illnesses
280 patients were taking the dietetic preparation, the effect of this medicament on the general condition has been observed at 114 patients.
We followed the general condition, the movability of 21 patients with a brain tumour, who had a bad general condition and who were in the terminal phase, predominantly they were unmobile and were treated with a symptomatically therapy. Between the third and the forth week a visible recovery has been noticed so that the majority of the patients get increasingly attack-free, they become progressively mobile with help, some of them are able in the second month of taking to read alone the papers and to watch TV.
At 40 patients with a primary lung tumour, who are in the terminal phase, it has been noticed that between the third and the fourth week an improvement of the general condition has been recorded according to pain reduction, the improvement of the respiration as well as the movability. One patient who died in the third week was the only one who showed no signs of improvement, but reached rapidly a distinctive cachexis stage.
Furthermore we followed 53 patients with a carcinoma of the digestion section, who also were in the terminal phase of the illness with a distinctive cachexis stage, they showed a delayed effect of MEGAMIN according to only moderate recovery of the general condition which we put in connection with working place of MEGAMIN (intestinal section). In the third week we had 4 patients with a lethal exit, but we have to add that the suggested dose has not been taken because of nausea, vomiting and bad general condition.
In this short time period of observation of the effect MEGAMIN has found its place in the symptomatic therapy. We have noticed that it has come to a better compatibility of the chemotherapy as well as ray treatment with the addition of MEGAMIN. At some patients we could observe doublesonographic (?) and in the three-dimensional Power-Double-Technique (?) reduced circulation.
Summarised an obvious change of the life quality was stated, in which it comes to a clear improvement of the condition of the patients (movability, appetite, increase of weight).
2. Illnesses of the liver – chronic (virus-) hepatitis, cirrhoses
At 20 patients with chronic virus hepatitis already two weeks after giving 6 capsules daily, tiredness and flatulence disappeared, and after one month it comes to a reduction of GOT, GPT, -GT and bilirubin. We could not prove the marcer (?) of the virus hepatitis-DANN and –RNA at the majority of the patients.
At the decompensated cirrhoses it comes after seven days to a clear recovery of the general symptoms of aszites.
Patients with insulin in "depending" diabetes (24), who were treated with a peroral therapy, showed a clear reduction of the glucose value in the blood as well as a reduced request for the taking of oral medicaments for the insulin release. Two patients ended the oral antidiabetic-therapy and are now only on a diet.
4. Neurodegenerative illnesses
An extremely positive effect MEGAMIN showed at the multiple sclerosis in the early stage, while the results in the advanced stage with extended fibrosiation herd in the brain turned out essentially more modest. A positive effect was also recorded at the neurodermitis and at muscle dystrophy – respectively in the early stage.
MEGAMIN not toxic!
TMAZ, MEGAMINs basic substance has shown neither toxic nor mutagenic effects in acute, subchronic and cronic toxicology studies. These studies (according to the guidelines published by the Organization for Economic Cooperation and Developement, OECD) have been carried out in Ruder Boskovic Institute, Zagreb, Croatia.
THE ESTIMATE OF CORRELATION BETWEEN MEASURED TAS (Total Antioxidant Status) LEVEL AND NUMBER OF MEGAMIN -ANTIOXIDANT CAPSULES
We have measured TAS level at 33 individuals of which 22 were healthy and 11 were sick.
TAS value correlation of healthy individuals (22) shows significant value divergence especially of those who take smaller doses of MEGAMIN (1 to 7 capsules). We could have expected those results and they can be explained with biological variation and need of different number of capsules that usually have to be adjustable from case to case.
The other group that was consisted of individuals with malignant diseases (11 individuals with daily uptake of Megamin 12 capsules in average) had satisfying degree of correlation r = 0,67 between TAS and the number of capsules.
When the daily amount of MEGAMIN is more than 16 capsules there has been noticed a fast increase of TAS, what can bee seen in Table 2. These results show satisfying capacity of MEGAMIN antioxidant effects.
In Table 3 there is a comparison between the healthy individuals who take daily 3 capsules of MEGAMIN in average and the sick individuals with average daily amount of 12 capsules. The Table shows that in spite of good health condition of healthy individuals their TAS is lower than TAS of sick individuals what is the result of increased daily amount of MEGAMINcapsules.
Up today researches show the importance of origination of endogen free radicals as well as outer agents, which are additional source of free radicals.
Antioxidant therapy, especially on patients with low natural defensive system and on those suffering from already mentioned diseases, has been proved successful, but not in final phase of disease and not as a mono-therapy but as an addition of prescribed therapy.
Measurement of TAS should be practised at chronicle diseases after which the antioxidant therapy should be added. When there are big damages, what clinically mean progressive state of diseases, daily amount of antioxidant should be increased. But there has to be emphasised that antioxidants show the best effects when they are taken as a prevention.
Dr. Slavko Ivkovic
WITH MEGAMIN AGAINST FREE RADICALS AND DISEASES.
In recent years more and more time is spent in discussions about free radicals as the most responsible factors of many pathological conditions in an organism.
90% of different diseases (malignant, cardiovascular, diabetes, arthritis, neurodegenerative diseases etc.) as well as ageing appear as the consequences of cellular functional disorder and the damage of the cell itself, what is caused by direct or indirect influence of Oxygen Free Radicals. Free radicals supervise many processes in transmission of signals and expression of genes.
Because of all that, powerful multinational pharmaceutics companies try to make products which can supervise and regulate redox processes in the cells and tissues and that way to control the diseases. There are two different groups of such products: one is based on development of powerful liquid antioxidants and the other on the development of powerful solid antioxidants. In the development of the first antioxidants groups from the USA and Japan have distinguished themselves from the others and in the development of solid antioxidants a group from Zagreb has gone the most further. As the result of all those attemptations and researches a powerful antioxidant and imunomodulate MEGAMIN has appeared on the Croatian market.
WHAT ARE THE FREE RADICALS?
Free radicals can be defined as chemical species which can have one or more unpaired electrons in the outer layer (free electron) and because of that they cause different chemical reactions which lead to changes on the biomolecular level. In the search for the "lost" electron free radicals start a chain of chemical reactions with cellular lipids proteins, carbohydrates and enzymes as well as the cellular DNA what leads to the damage of the cell and at the end to the death of the cell.
Smoking, incorrect eating habits, different radiation and exposure to harmful chemicals decrease natural defensive power of an organism and increase the danger of free radicals aggression. For example: science studies have shown that smoking individuals have DNA 30-40 times more damaged than non-smoking individuals. So, cells and tissues are constantly exposed to the affection of oxygen radicals which are taken in from outside or of oxygen free radicals which are formed as the secondary products of some phases of metabolism processes, and because of that cells and tissues are in the constant danger of oxidative changes.
With its own antioxidant system (e.g. native enzymes) the cell protect itself from their harmful effects. But during some time that defensive system weakness and under the influence of free radicals it becomes insufficient and as the result of all of that appears the damage of the cell and at the end a disease.
An organism uses two different defensive mechanisms: one is its own which control creation of free radicals and repairs damaged tissues and the other one is natural antioxidants such as vitamins A, C and E, carotenoids, flavonoids, coenzymes Q 10 and others. These natural antioxidants are taken into the organism by food and different vitamin and mineral products. Some of those vitamin and minerals products are about to become a medicine of the 21st century.
As a powerful antioxidant and regulator of a redox process in cells MEGAMIN belongs to those products.
When MEGAMIN should not be taken?
Miroslava Stiplosek MD.
The effect of the dietetic preparation MEGAMIN on the life quality of 58 patient have been examined, who had malignant illnesses, the influence on life quality has been watched, the reduction of the complaints of the patients during chemotherapy and ray treatments as well as the compatibility of the mentioned dietetic preparation.
To the examination I stepped as a person, who wants to help patients who have heavily fallen ill. The decision, to give this dietetic preparation also to this group of patient, fell when some of my family members and friends as well as I had taken MEGAMIN. No side effects were noticeable; on the contrary, we felt psychologically as well as physiologically better. We all had blood tests before and during the taking of the preparation. During the whole time there were no deviation of the physiological results.
The criteria for the choice of the patients were the following: The diagnosis of a malignant illness with a valid medical documentation, not depending on sex and age. The patients took part at the series of experiments on the request of their own or of next relatives, these are patients, who already have had standard treatments. In addition we had fixed the exclusion criteria: No definite diagnosis, a declining attitude of the next relatives, patients in the preparation phase of a bone marrow transplantation as well as pregnant and stanching women. Breaking of criteria was over-sensitiveness on the preparation and side effects during the taking of this dietetic preparation.
We divided all 58 patients up, under consideration of the illness duration, into two large groups:
1.Patients who had been stated a malignant illness before March 1997 (at the earliest 1994)
2.Patients who had been stated a malignant illness after March 1997
In the first group 27 patients were accompanied, 12 of these are still alive, while 15 patients have died. The second group consists of 31 patients, 23 of these are still alive and are still in treatment, while 8 of them have died.
We have divided the same group, depending on the condition of the illness, into three subgroups:
1.Patients with operable malignant illnesses (40 patients)
2.Patients with inoperable malignant illnesses (12 patients)
3.Patients with symptomatic illnesses (6 patients)
The patients, who have died, were in the terminal phase of the malignant illness, they were predominantly bedridden and have been symptomatically given therapy (under application of various analgetica, when required). With regard to the life quality from the beginning of the treatment with MEGAMIN until the moment of death, the psychological situation has improved from all of them. It came to an appetite increase, they gained weight and the request for analgetica sank.
Due to the various anamnestic details of the next relatives and due to the contact with the patients, four patient groups are being distinguished:
1.Patients who are able to leave occasionally the house alone (8)
2.Patients who are able to live at home with still tolerable tumour manifestation (8)
3.Bedridden patients with satisfying emotional and physical conditions, without sleepnessesses or stronger distinctive pain, with better appetite and the ability to i. e. watch TV and similar (4)
4.Patients without or with only short-term positive effect at only irregular and occasional taking of the preparation (3)
During the observation of all patients it has shown, that the support on the part of the family is of a great meaning.
Separate representation of the died patients:
1.Diagnosis: Neoplasis Pancreas Head (Sepember 1997)
Beginning of taking MEGAMIN: January 1998
Died: End of July 1998
The patient has been mobile until the last week, he was driving the car, has gone to the sea, has stayed there, has worked in the garden and in the house, has died after a sudden feeling of weakness at the second stationary day.
2.Diagnosis: Plate Epithel carcinoma lateral left Bronchus (February 1998)
Beginning of taking MEGAMIN: February 1998
Died: End of October 1998
The 82-old patient has been dismissed to die at home, soon after taking MEGAMIN she becomes more mobile, she is carrying out housework, sweeping the yard, has a good appetite, is gaining 5 kg of weight and she is telling her neighbours that she has recovered. She is not complaining about pain or aggravated breathing, she is full of confidence. In the heat period in August, she dies two weeks lying in the bed.
3.Diagnosis: inoperable Rectumblastom (June 1995)
Condition after Anus praeter naturalis sigmoideus definitivus
Fistula vesico-rectalis (December 7th, 1997)
Beginning of taking MEGAMIN: February 1998
Died: End of October 1998
The patient spent most of the time in bed, after taking MEGAMIN, however, he moke frequently got up, sometimes he even went to his workshop, he drove a car, visited friends, this summer he distilled schnapps and was singing in his yard. He watched TV. During the whole illness duration he went from time to time to the hospital were he was treated with a symptomatic therapy in addition to his blood substitute. At the day of his last hospital visit, he was found dead in the morning. The doctors of the surgical department were surprised that a so heavy ill patient could get by with so low quantities of analgetics.
The mentioned people as well as all other patients, who have died, were living longer to the surprise of their general doctors.
Patients who are still under observation (35):
All patients have metastases, 20 of them in the lymph node and 15 patients in more distanced organs (brain, lung, liver, bones). 12 patients had already chemotherapy and ray treatments and 23 patients have just started a zytostatic therapy.
At all patients the life quality has been followed:
the emotional situation improved, sleepnessess, depressions decreased, life will increases.
stress- and frustration tolerance increases
the physical situation improves: better movability, pains are less distinctive or not anymore there, the ability for carrying out daily works are regained,
Appetite increase, weight increase, regulation of excrement,
one group of patients who had been treated with chemotherapy or had ray treatment, were more consistent to the therapies, they more seldomly complain about nausea and are recovering faster after chemotherapy/ray treatments.
Separate representation of the patients in the course of taking MEGAMIN:
1.Diagnosis: Lymphosarcom of the left thigh (Beginning December 1997)
Abdomen-CT: multiple metastases (beginning December 1997)
Beginning of taking MEGAMIN : middle of February 1998
Is taking daily uninterrupted 30 capsules of MEGAMIN.
The tumour at the left thigh has shrunk from the size of a head of an adult to the size of a grapefruit. The skin above the tumour has got back its normal colour; the vessel drawing above the tumour has disappeared. The tumour growth on the neck has completely disappeared as well as the 20 other changes, which could have been seen on the scalp.
Due to the heaviness of the illness the therapy has been started with three times of one capsule MEGAMIN at the first day, the dose has been increased all two days, until a dose of 30 capsules daily has been reached. The immobile patient became completely mobile, this summer he walked daily up to two miles, since one and a half month he is walking just upright as before when he was healthy. He was at the sea, swam, he gained weight about 25 kg. On request of his parents, the patient has not been explained about his diagnosis, so that he could not be won for the necessary examinations.
2.Diagnosis: Colon carcinoma, condition after operative intervention (1994)
Metastases in the liver and lungs (classified as inoperable). The control examination, made in the middle of February 1998, stated metastatic changes as results of the reason illness, namely in the upper segment of the right lungs rag (19 x 13 mm) and in the area of the liver (diameter 6-cm).
Beginning of taking MEGAMIN: Beginning of May1998.
An ultrasound examination of the liver (October 1998) showed an unobtrusive echo in the area of the metastasis diagnosed in February. The x-rays of the lung do not show a stamp form of metastasis shadows.
The number of capsules of the dietetic preparation MEGAMIN has also been increased of this patient, to take at October 10 th, 1998 every half hour one capsule of MEGAMIN. With the intention to strengthen the effect, he took two capsules and noticed that the area of the skin above the metastasis in the liver became warmer for some degrees. After that he reduced the dose on one capsule every half-hour, but he enlarged the dose of earlier taken morphine or other opiates that he was taking at night. Already one week after taking this MEGAMIN-dose he is not taking opiates anymore. This patient also declines further examinations since February 1998. Only now since his condition has improved, he is prepared to make further necessary examinations.
Besides the life quality the compatibility and possible appearing side effects have been watched at all patients. All patients have been consistent about MEGAMIN and no side effects arose.
With consideration on all these patients who have been observed as well all those who have been reporting themselves voluntarily with their various diagnoses, I cannot answer this question: "When MEGAMIN should not be taken?"